Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deupsilocin - Helus Pharma

Next Previous
Drug Profile

Deupsilocin - Helus Pharma

Alternative Names: CYB-003; Deuterated psilocin - Helus Pharma; Deuterated-Psilocin - Helus Pharma; HLP-003

Latest Information Update: 29 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cybin
  • Developer Cybin; Helus Pharma
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Ethylamines; Indoles; Organic deuterium compounds; Phenols; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Discontinued Alcoholism; Psychiatric disorders

Most Recent Events

  • 21 Jul 2026 Helus Pharma completes enrollment in the phase III APPROACH trial in Major depressive disorder (Adjunctive treatment) in USA (PO) (NCT06564818)
  • 29 Jun 2026 Helus Pharma announces intention to submit NDA to US FDA for Major Depressive Disorder in 2028
  • 09 Mar 2026 Chemical structure information added.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top